Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Non-profit
  • Arts
  • Technology
  • Books
  • Entertainment
ncarol.com

HCPs Anticipate Disruption of Oral T2D Landscape by Division
ncarol.com/10211391

Trending...
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • Community-Based Marriage Enrichment Support
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
RESEARCH TRIANGLE PARK, N.C. - ncarol.com -- A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why. According to newly published data by market research from Vivisum Partners, LLC., new arrivals are likely to take some pieces of the current share of oral treatments on market, but it may be enough to cause some dents in multiple treatments due to viable alternatives.

The current market holds a lot of excitement for the oral type 2 diabetes pipeline for drugs that are just as comparable in tolerability, but may differ on other clinical attributes, such as dosing. The most potential risk for a more established treatment will be pipeline products gaining more access.

For example, according to Oral T2D Clinical Pipeline, many HCPs expect oral Insulin's efficacy to be slightly or much better than current oral T2D treatments. In dosing, oral Insulin is believed to be slightly better according to a significant percentage of endocrinologists. Familiarity with HCPs could represent much of the difference in access for patients.

More on ncarol.com
  • O2 Fitness Opens New Signature Location in Pittsboro, NC
  • Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
  • Lamaze International and Plumtree Baby Launch New Childbirth Education Materials
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST

Despite significant excitement for physicians who are familiar with oral insulin there is significant excitement. There is an overall low level of familiarity with other oral T2D pipeline medications. Only 21% of HCPs are familiar with oral insulin, which is the highest percentage of familiarity among any clinical pipeline treatment.

Vivisum Partners surveyed Endocrinologists and HCPs about each oral type 2 diabetes pipeline therapy. The survey results specify their degree of excitement, "HCPs are evenly split between being excited (48%) vs. ambivalent (48%) towards Sotagliflozin", -said Vivisum's Oral Type 2 Diabetes strategist Patrick Brunell. He adds, this suggests that HCPs are interested in Sotagliflozin, but remain skeptical on how well it will perform in the market." Most Endocrinologists (80%) believe that Sotagliflozin will have about the same level of access as current diabetes medications.

Many of the metrics used in the report show that established treatments may have to get used to sharing larger portions of the Oral T2D marketplace. Relying on brand recognition may or may not be enough. Oral T2D Clinical Pipeline Analysis, https://vivisumpartners.com/reports/new-diabetes-medications-clinical-pipeline-analysis/, published in January 2023 by Vivisum Partners, examines each oral type 2 diabetes drug's strengths and weaknesses across six key clinical attributes:
  • Access
  • Dosing
  • Efficacy
  • Safety
  • Support
  • Tolerability

ABOUT VIVISUM PARTNERS, LLC

More on ncarol.com
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Walnut Hills Launches Off-Grid Hempcrete Homes and Eco-Retreat in Western NC
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.

Contact
Candice Smith
***@vivisumpartners.com


Source: Vivisum Partners, LLC

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Bang Bang Burgers and Orrman's Cheese Shop Unleash The Mac Daddy for National Mac & Cheese Day
  • Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
  • Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
  • Community-Based Marriage Enrichment Support
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Scott Burton Releases Chaos: The Weight of a Memory, a Poetic Journey Through What Still Lingers
  • The Business Hyve Opens Waitlist for Groundbreaking Community Built for Small Business Success
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
_catLbl0 _catLbl1

Popular on ncarol.com

  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 113
  • csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
  • Let's Talk Series: At the Crossroads: Immigration Today
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • Beyond the Template: Why Custom Web Design is a Power Move for Small Businesses
  • DumpEmDumpsterRentals.com Launches in Charlotte, Offering 10% Off 3-Day Rentals
  • Local Clinic Fills the Gaps Politicians Don't Want to Talk About

Similar on ncarol.com

  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
  • $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
  • $750 Million Market Projected to Reach $3.3 Billion Globally in 2034 for New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharma, Inc
  • ARCH Dental + Aesthetics Unveils New Website for Enhanced Patient Experience
  • Juventix Regenerative Medical Announces Strategic Partnership with Juvasonic® to Expand Needle-Free Biologic Delivery Platform
  • CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
  • Phoenix Implant Clinic Introduces Upfront Cost Page to Strengthen Patient Trust
  • Sumis Partners Launches, Uniting Industry Leaders to Redefine Life Sciences Consulting
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute